Sector News

Gilead Sciences and Kite Pharma acquire Cell Design Labs

December 12, 2017
Life sciences

Biotech giant Gilead Sciences Inc. and its Kite Pharma Inc. subsidiary in Santa Monica are buying Cell Design Labs Inc. for up to $567 million as the battle to develop cancer-targeting cell therapies heats up.

Gilead of Foster City, which bought Kite Pharma in August for $12 billion, said Thursday the deal to acquire the Emeryville-based lab would close shortly.

“The transaction will build on Gilead’s recent acquisition of Kita Pharma Inc. and has the potential to help the Gilead and Kite organizations accelerate the development of next generation cellular therapy candidates,” the companies said in a joint news release.

The transaction includes an up-front payment of $175 million, plus added payments of $322 million upon meeting certain milestones. About 12.2 percent of shares in Cell Design held by Kite are included as part of the deal.

Among Cell Design Labs’ chief investors and board members is Los Angeles biotech maverick Dr. Arie Belldegrun, founder of Kite Pharma and now a major advisor.

The acquisition strengthens Gilead’s position as developer of chimeric antigen receptor T-cell therapy (CART-T) drugs, a new class of treatments that transform a patient’s immune cells to target cancer.

In October, Kite won federal approval for a Yescarta CAR-T treatment for adults with non-Hodgkin’s lymphoma. In August, competitor Novartis AG won federal approval for the first cell-based cancer treatment in the U.S. for acute leukemia.

Cell Design will bring to the Gilead fold two tech platforms that can be applied to cell therapy and early stage treatments for prostate cancer and a type of blood cancer.

By Dana Bartholomew

Source: LA Business Journal

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach